Literature DB >> 18228554

Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS.

Deborah K Glencross1, George Janossy, Lindi M Coetzee, Denise Lawrie, Hazel M Aggett, Lesley E Scott, Ian Sanne, James A McIntyre, Wendy Stevens.   

Abstract

BACKGROUND: In order to expand the treatment of human immunodeficiency virus-1 (HIV) infected patients in Africa, millions will require cost-effective CD4 counts. Supporting laboratories therefore, need to move away from crisis management and haphazard practices to organized pathology services. The authors reviewed the performance of the simplified single platform (SP) PanLeucogated (PLG) CD4 methodology, introduced into 52 laboratories across the South African National Health Laboratory Service (SA-NHLS), with a proactive approach to training, internal quality control (IQC), and external quality assessment (EQA).
METHODS: Two-color flow cytometry for SP PLG (CD4/CD45) was combined with the sample-by-sample bead-count-rate (BCR) IQC for bead pipetting. PLG + BCR was validated versus conventional predicate SP and dual-platform (DP) 4-color flow cytometric methods used in the first world-on 1181 samples from 250 HIV+ patients followed longitudinally on anti-retroviral therapy (ART). EQA (accuracy) was performed through the United Kingdom National External Quality Assessment Scheme (UK-NEQAS). Further EQA was performed across the 52 SA-NHLS SP-PLG laboratories participating on the CD4 African Regional External Quality Assessment Scheme (AFREQAS), to assess both accuracy and/precision between NHLS PLG laboratories.
RESULTS: There was virtually no bias noted between SP PLG and SP predicate methods. On DP, bias and variability increased but the errors introduced were minor without affecting CD4-related clinical decisions. The simpler 2-color PLG was less expensive with additional advantages: CD4+ T-cells were discriminated from monocytes without a need for CD3-staining, and the training was faster and easier for the trainees and trainers alike. The accuracy of SP-PLG was satisfactory: all PLG results submitted to the UK NEQAS were within +/-1 Trimmed Standard Deviation (SD) of the UK NEQAS CD4 Pool Trimmed Mean. Further, on the CD4 AFREQAS, the SA-NHLS laboratories using SP-PLG + BCR showed better precision (mean %CV = 7.2%) than the CD4 methods employed in other laboratories in Africa (mean %CV = 10.7%) or on other continents (mean %CV = 12.9%). PLG + BCR accommodated high workloads, exceeding 3,000 tests/laboratory/month, with capacity for further growth around 10% per month across the SA-NHLS.
CONCLUSIONS: The superior performance of PLG + BCR over other methods has been demonstrated. In resource-conscious countries, where large-scale ART is being introduced, flow-cytometry using PLG + BCR can make a significant impact-due to simpler operation, easier training, stricter quality assurance, and better cost-efficiency. These cost-effective flow methods can legitimately replace the more cumbersome predicate technology of the first world for ART monitoring whilst accommodating an ever-expanding national ART program and consequent extremely high workloads reached country-wide. Copyright 2008 Clinical Cytometry Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228554     DOI: 10.1002/cyto.b.20384

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  31 in total

1.  Perspectives on introduction and implementation of new point-of-care diagnostic tests.

Authors:  Kara M Palamountain; Jeff Baker; Elliot P Cowan; Shaffiq Essajee; Laura T Mazzola; Mutsumi Metzler; Marco Schito; Wendy S Stevens; Gloria J Young; Gonzalo J Domingo
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

2.  Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa Collaboration.

Authors:  Mary-Ann Davies; Andrew Boulle; Brian Eley; Harry Moultrie; Karl Technau; Helena Rabie; Gilles van Cutsem; Janet Giddy; Robin Wood; Matthias Egger; Olivia Keiser
Journal:  Trop Med Int Health       Date:  2011-08-11       Impact factor: 2.622

3.  Efficient on-chip isolation of HIV subtypes.

Authors:  ShuQi Wang; Matin Esfahani; Umut A Gurkan; Fatih Inci; Daniel R Kuritzkes; Utkan Demirci
Journal:  Lab Chip       Date:  2012-03-06       Impact factor: 6.799

4.  The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure.

Authors:  Mary-Ann Davies; Andrew Boulle; Karl Technau; Brian Eley; Harry Moultrie; Helena Rabie; Daniela Garone; Janet Giddy; Robin Wood; Matthias Egger; Olivia Keiser
Journal:  Trop Med Int Health       Date:  2012-09-14       Impact factor: 2.622

5.  VERITAS?: A time for VERIQAS™ and a new approach to training, education, and the quality assessment of CD4+ T lymphocyte counting (I).

Authors:  David Barnett; Liam Whitby; John Wong; Raul Louzao; John T Reilly; Thomas N Denny
Journal:  Cytometry B Clin Cytom       Date:  2011-10-13       Impact factor: 3.058

6.  Performance evaluation of the MBio Diagnostics point-of-care CD4 counter.

Authors:  Cathy Logan; Monique Givens; Jeffrey T Ives; Marie Delaney; Michael J Lochhead; Robert T Schooley; Constance A Benson
Journal:  J Immunol Methods       Date:  2012-10-11       Impact factor: 2.303

7.  Tree-Based Methods for Discovery of Association between Flow Cytometry Data and Clinical Endpoints.

Authors:  M Eliot; L Azzoni; C Firnhaber; W Stevens; D K Glencross; I Sanne; L J Montaner; A S Foulkes
Journal:  Adv Bioinformatics       Date:  2010-01-21

8.  CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.

Authors:  Christopher J Hoffmann; Michael Schomaker; Matthew P Fox; Portia Mutevedzi; Janet Giddy; Hans Prozesky; Robin Wood; Daniela B Garone; Matthias Egger; Andrew Boulle
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

9.  A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey.

Authors:  Jonathan M Kagan; Ana M Sanchez; Alan Landay; Thomas N Denny
Journal:  For Immunopathol Dis Therap       Date:  2015

Review 10.  CD4 immunophenotyping in HIV infection.

Authors:  David Barnett; Brooke Walker; Alan Landay; Thomas N Denny
Journal:  Nat Rev Microbiol       Date:  2008-11       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.